anterior ischemic optic neuropathy

Life Biosciences, a company Sinclair co-founded, took the same three gene idea into monkeys.

They used a model of something called NAION, non-autoritic anterior ischemic optic neuropathy, which is a miserable name, but a sudden loss of blood flow to the optic nerve.

Think of it as a stroke of the eye.

At a vision research meeting in 2023, they reported that OSK improved visual function and helped more nerve fiber survive.

It is permission to put it in people and find out if it's safe.

On June 9th, 2026, Life Biosciences announced that the first patient had been dosed.

The trial is phase one, about 18 adults, open angle glaucoma and NAION, one injection into one eye, then doxycyline for eight weeks to wake the genes.

The official first job is safety and tolerability.

Because some people are having eye damage and vision loss.

And this is a condition known as NAION.

And it's a sudden loss of vision caused by reduced blood flow to your optic nerve.

All right.

Which is exactly why Life Biosciences advanced their pipeline into non-human primates before going to the FDA.

They used African green monkeys to test the ER100 therapy on a condition called NAION.

Non-arteritic anterior ischemic optic neuropathy.

Basically an eye stroke.

They start with an exceptionally low dose of the vector in a small group.

If the Data Safety Monitoring Board confirms there's no severe toxicity, like acute inflammation, they authorize a higher dose for the next group.

But the second cohort, targeting NAION, is much harder logistically.

It is immensely challenging.

Are we ready for robots to do the mundane tasks around the household? Ajay Kumar is here.

He is, uh, smart home and robotics editor for our friends at, uh, CNET, the go-to source when it comes to everything tech.

And, uh, Ajay, welcome to the show.

How are you?

You just have to basically have a TOD on anything you wanna transfer, beneficiaries listed on all your financial stuff, bank savings with whoever's name you want it to go to.

You avoid taxes.

You avoid everything And the main reason they want you to write a will, 'cause guess who gets paid for it? The lawyers do.

Well, the lawyers do.

They have eye strokes.

And this is based on a study now that is linking some of the GLP-1s to this very rare NAION.

I'm not going to pronounce it, but it's an optic neuropathy.

And it causes this acute optic nerve injury in adults over 50 that makes them lose sight in at least one eye.

The drugs millions of Americans are taking for weight loss and diabetes.

A sudden and possibly irreversible eye condition called NAION that can lead to permanent blindness.

There are no known treatments.

I woke up one morning and I was like, what is wrong with my eye? There was no warning sign at all.

While a study by the American Academy of Ophthalmologists did not find evidence of a consistent overall increase in N-A-I-O-N risk in the available data, adding that more research needs to be done.

Meanwhile overseas, a different story.

The European Medicines Agency concluded NAION is a very rare side effect, and the EU has added it to the labels for Ozempic and Wegovy.

But the wildly popular drugs have proven to be effective in fighting diabetes and weight loss, and medical experts say people considering taking them should speak with their doctors.